newsfilter
← Latest News
Business Wire·

New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System

OGN
  • Organon presented real-world evidence at the American College of Rheumatology Annual Meeting in Orlando, Florida, regarding the transition from HUMIRA to HADLIMA within the US Veterans Affairs Healthcare System.
  • The analysis covered 16,322 patients who switched from originator HUMIRA to biosimilar HADLIMA over a 12-month follow-up period.
  • The switchback rate from HADLIMA to HUMIRA was 1.3%, which is significantly lower than the 16-18% rates often cited in scientific literature.
  • Treatment adherence metrics remained similar before and after the switch for the patient cohort.
  • The average first-year per-patient pharmacy cost decreased by $8,100 across all indications in the switch cohort.
  • The transition resulted in an estimated total savings of $132 million for the Veterans Affairs Healthcare System.
  • HADLIMA was exclusively selected by the VA to replace HUMIRA on its national formulary in 2024.
  • The study cohort had a mean age of 60 years, with 87% male participants and 75% white participants.
  • Rheumatoid arthritis was the most common diagnosis in the switch cohort at 21.9%, followed by psoriatic arthritis at 8.4% and ankylosing spondylitis at 7.6%.
  • HADLIMA is indicated for multiple conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
  • Safety warnings for HADLIMA include increased risks of serious infections, malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematologic reactions, congestive heart failure, autoimmunity, and the need to avoid live vaccines.